Cleerly vs Elucid (2026)
Both sell coronary plaque analysis as a service on CT angiography, and both are billed under the same Category I plaque code from January 2026. Cleerly adds an ischemia estimate, validated in the prospective, multicenter CREDENCE trial against invasive FFR, and publishes its security reports for download. Elucid classifies plaque against histology, including lipid rich necrotic core, and covers carotid as well as coronary CT; its fractional flow reserve and stenosis outputs are pending FDA review. If ischemia and prospective trial evidence matter most, start with Cleerly. If plaque composition and carotid coverage matter most, start with Elucid.
- Ischemia is the question: Cleerly ISCHEMIA was validated in the prospective, multicenter CREDENCE trial against invasive FFR, and K231335 reports its figures with counts.
- You want the security reports without asking: the trust center offers SOC 2 Type 2 and HITRUST reports for download.
- Reimbursement drives the decision: Cleerly publishes a payer policy lookup tool alongside its Category I codes for plaque analysis and ISCHEMIA.
- Plaque composition is the question: PlaqueIQ classifies plaque components against histology, including lipid rich necrotic core.
- You read carotid CT: the carotid application launched in October 2025 under the same analysis.
- You want the analysis done for you: Elucid analysts segment each study, and physicians review the result and can request rework.
This comparison is published by AI Health Index, an independent research platform that compares healthcare AI vendors objectively. Cleerly and Elucid are each graded against the same capability taxonomy, from each vendor's own public materials and the regulatory record, under the AI Health Index verification standard. No vendor pays for placement, and no vendor has reviewed this page. How this evidence is graded
Plain facts
| Fact | Cleerly | Elucid |
|---|---|---|
| Primary category | Radiology & Imaging AI | Radiology & Imaging AI |
| Founded | 2017 | Not recorded |
| Headquarters | Denver, Colorado, United States | Boston, Massachusetts, United States |
| Website | cleerlyhealth.com | elucid.com |
Side by Side
Select any grade to read the note behind it.
Each vendor in one paragraph
Written to be quoted whole. Each paragraph opens the AI Health Index profile of the vendor: what the product is, who buys it and what it does.
Cleerly applies AI to coronary CT angiography to quantify and characterize atherosclerotic plaque and estimate ischemia without an invasive test. Cleerly Labs, web based analysis cleared in 2020, measures plaque volume, composition, length and location and stenosis on CCTA from any scanner; Cleerly ISCHEMIA, cleared in 2023 (K231335), estimates vessel level ischemia as a diagnostic aid; Cleerly COMPARE tracks change between scans.
Source: AI Health Index, September 2026
Elucid analyzes coronary and carotid CT angiography to quantify and classify atherosclerotic plaque, including lipid rich necrotic core, the plaque type most linked to heart attack and stroke. Plaque-IQ, cleared by the FDA in September 2024 (K241524), classifies plaque components against ground-truth histology rather than fixed Hounsfield unit ranges, an approach the company calls CT Virtual Histology, and reports patient, vessel and lesion level composition, stenosis and CAD-RADS scoring; the carotid application launched in October 2025.
Source: AI Health Index, September 2026
Questions buyers ask
How do Cleerly and Elucid work with the EHR?
Cleerly operates as a CCTA analysis service that returns a physician report, sitting in the cardiac imaging and reporting pathway rather than integrating deeply with the EHR.
With Elucid, the integration work a site takes on is not described either. From the AI Health Index, drawn from each vendor's own published materials and the regulatory record, verified September 27, 2026. No vendor pays for placement.
How are Cleerly and Elucid priced and sold?
Cleerly publishes billing guidelines, coverage pages and a payer policy lookup tool: AI plaque analysis of coronary CT carries Category I CPT code 75577 from January 2026, ISCHEMIA is billable under Category I code 75580, and Medicare contractor and commercial payer policies are reported to cover more than 86 million lives.
Elucid publishes the CPT codes that apply (CCTA 75574; Plaque-IQ under Category III codes 0623T to 0626T and, from January 2026, Category I 75577) and a state by state insurer coverage map, and says 70 percent of insured US lives have positive coverage policies; four of seven Medicare contractors, EviCore and UnitedHealthcare cover AI plaque analysis. From the AI Health Index, drawn from each vendor's own published materials and the regulatory record, verified September 27, 2026. No vendor pays for placement.
Which settings and specialties do Cleerly and Elucid cover?
Cleerly Labs analyzes CCTA from any CT scanner for patients with known or suspected coronary artery disease, and ISCHEMIA estimates vessel level ischemia as a diagnostic aid; COMPARE tracks change between scans. ISCHEMIA was validated in stable patients referred for non-emergent invasive angiography at 23 centers in and outside the US, with results reported for both.
In Elucid's case, the plaque classification is validated against histology, and the company markets it for a broad insured US population. From the AI Health Index, drawn from each vendor's own published materials and the regulatory record, verified September 27, 2026. No vendor pays for placement.
What evidence is published for Cleerly and Elucid?
For Cleerly, a post-hoc analysis of the PACIFIC trial compared it with FFRCT, PET and SPECT against invasive FFR, and the international CONFIRM2 registry links quantified plaque burden to risk. The company's claims that ISCHEMIA was more accurate than FFRCT and stress testing and was the only non-invasive ischemia test prognostic of later events come from its own analyses of CREDENCE and PACIFIC.
Elucid publishes correlations between Plaque-IQ and pathologist-read histology from the data behind its clearance (K241524): total plaque r = 0.99, calcified 0.95, non-calcified 0.86, and lipid rich necrotic core 0.88, without the number of specimens or patients. From the AI Health Index, drawn from each vendor's own published materials and the regulatory record, verified September 27, 2026. No vendor pays for placement.
Related comparisons
Other published head to head assessments involving these vendors or their closest peers. The full set for this category is on the Clinical Decision Support page.
Elucid's histology correlations are published without case counts. Cleerly COMPARE is marketed without an identified clearance. Payer codes describe what a provider recovers, not what either vendor charges, and neither publishes a price.